Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

Compared to synthetic drugs, natural plant extracts offer the advantages of being suitable for long-term consumption, having ...

Psychiatrist Joanna Moncrieff indicts her entire industry for falsely pushing deadly drugs as a “treatment” for depression.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

During his Senate confirmation hearing to serve as Health and Human Services Secretary, Robert F. Kennedy, Jr. suggested ...

Some herbs can interfere with the action of drugs or otherwise make symptoms worse. Nonherbal supplements that may help treat depression include S-adenosyl methionine (SAMe) — a synthetic form ...

Pharmacodynamics includes interactions of a drug with receptors, transporters and downstream targets. Although the primary mechanism of action for antidepressants is thought to involve ...

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...

According to the news release, patients can expect to see improvements in depressive symptoms in 28 days—and maybe as quickly as 24 hours—without also relying on daily antidepressant pills.

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...